Akeso Invests to Boost Lung Cancer Drug Production

China-based biotech company Akeso is making significant investments to expand the production capacity of its lung cancer drug. In an exclusive interview with Bloomberg, the company's CFO, Bing Wang, stated that they expect demand for the drug to increase both in China and the United States. This investment follows the company's presentation of positive results for the drug at the American Society of Clinical Oncology (ASCO) annual meeting. Akeso aims to expand its manufacturing facilities to meet growing market demand. This is not investment advice.

📊 AKSGY — Piyasa Yorumu

▲ up · 65%

The news indicates that Akeso will invest to increase production of its lung cancer drug. This points to the company's growth potential and demand for the drug. Technical indicators also give positive signals: RSI at 61 is above the neutral zone, the MACD line is above the signal line, and the price is above both the 20-day and 50-day moving averages. A 2.2% increase in the last 24 hours confirms investor interest. An upward movement can be expected in the short term, but cautious optimism should be maintained as the overbought zone has not been approached.

RSI 14

61.0

MACD

0.03

24h Δ

2.21%

Canlı Grafikler